Embecta Corp. Announces Quarterly Dividend of $0.01 (NASDAQ:EMBC)

Key Points

• Quarterly dividend: Embecta declared a quarterly dividend of $0.01 per share with an ex‑dividend/record date of May 28 and a payment date of June 15.
• Earnings miss and weaker revenue: Embecta reported Q results of $0.27 EPS versus $0.42 expected and revenue of $221.8M (below the $235.7M consensus), with revenue down 14.4% year‑over‑year and FY2026 guidance set at $1.55–$1.75 EPS.
• Stock reaction and valuation: Shares tumbled $5.35 to $3.90 on heavy volume, while the company trades with a market cap around $231M and a P/E of 1.65, near its one‑year low of $3.89.

Embecta Corp. (NASDAQ:EMBC - Get Free Report) declared a quarterly dividend on Tuesday, May 5th. Stockholders of record on Thursday, May 28th will be given a dividend of 0.01 per share on Monday, June 15th. This represents a c) annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Thursday, May 28th.

Embecta has a payout ratio of 21.0% meaning its dividend is sufficiently covered by earnings. Research analysts expect Embecta to earn $2.86 per share next year, which means the company should continue to be able to cover its $0.60 annual dividend with an expected future payout ratio of 21.0%.

Embecta Stock Performance

Shares of NASDAQ EMBC traded down $5.35 during midday trading on Tuesday, hitting $3.90. 15,928,053 shares of the stock traded hands, compared to its average volume of 966,147. The firm has a 50-day moving average of $9.26 and a two-hundred day moving average of $11.27. The firm has a market capitalization of $230.96 million, a P/E ratio of 1.65 and a beta of 1.09. Embecta has a one year low of $3.89 and a one year high of $15.55.

Embecta (NASDAQ:EMBC - Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported $0.27 EPS for the quarter, missing analysts' consensus estimates of $0.42 by ($0.15). Embecta had a negative return on equity of 26.66% and a net margin of 12.92%.The company had revenue of $221.80 million during the quarter, compared to the consensus estimate of $235.67 million. During the same period in the prior year, the business posted $0.70 earnings per share. Embecta's revenue for the quarter was down 14.4% compared to the same quarter last year. Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. Equities analysts forecast that Embecta will post 2.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Embecta

Institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. raised its holdings in Embecta by 39.5% during the third quarter. JPMorgan Chase & Co. now owns 434,822 shares of the company's stock valued at $6,135,000 after acquiring an additional 123,113 shares during the period. Jefferies Financial Group Inc. grew its position in shares of Embecta by 40.4% during the third quarter. Jefferies Financial Group Inc. now owns 1,884,875 shares of the company's stock valued at $26,596,000 after purchasing an additional 542,162 shares in the last quarter. Public Sector Pension Investment Board grew its position in Embecta by 57.7% in the third quarter. Public Sector Pension Investment Board now owns 314,129 shares of the company's stock worth $4,432,000 after acquiring an additional 114,902 shares in the last quarter. Teacher Retirement System of Texas grew its position in Embecta by 365.7% in the third quarter. Teacher Retirement System of Texas now owns 372,451 shares of the company's stock worth $5,255,000 after acquiring an additional 292,477 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in Embecta in the fourth quarter worth about $5,178,000. 93.83% of the stock is owned by institutional investors.

About Embecta

Embecta Corp NASDAQ: EMBC is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.